Bromodomain and extraterminal (BET) protein inhibition of IgG/IgE production in murine B cells is counter‐balanced by a strong Th2 bias

Abstract Objectives Inhibitors of bromodomain and extra terminal domain (BET) proteins are a new and growing class of anti‐cancer drugs, which decrease oncogene expression by targeting superenhancers. Antibody production is another physiological process relying on superenhancers, and it remains to b...

Full description

Bibliographic Details
Main Authors: Zeinab Dalloul, Marie Best, Pauline Chenuet, Iman Dalloul, Sandrine Le Noir, Dieudonnée Togbé, Mylène Gador, Bernhard Ryffel, Valerie FJ Quesniaux, Yolla El Makhour, François Boyer, Jean‐Claude Aldigier, Jeanne Cook‐Moreau, Nicolas Fazilleau, Michel Cogné
Format: Article
Language:English
Published: Wiley 2021-01-01
Series:Clinical & Translational Immunology
Subjects:
Online Access:https://doi.org/10.1002/cti2.1280